Doxorubicin Hydrochloride 200mg Injection (Doxorubicin Hydrochloride)

Doxorubicin Hydrochloride 200mg Injection is a medicine used for treating various cancers. The active component of this drug is doxorubicin. The medicine works by inhibiting the growth and division of cancer cells by interfering with their DNA and the action of the enzyme topoisomerase II. Even though doxorubicin hydrochloride 200mg injection is an effective medicine for chemotherapy, it has several adverse reactions, which include reduced numbers of blood cells and heart toxicity, especially with high cumulative doses.

However, the 200mg vial dosage does not imply that all patients will be prescribed 200mg. The dosing will depend on many factors such as body surface area, regimen, organ functions, and exposure to the anthracyclines. Doxorubicin injection should be administered only by oncologists; also, extra care must be taken when administering this medicine because extravasation of the medicine can result in significant tissue injury.

Doxorubicin injection is an effective chemotherapy drug that can be part of various treatment protocols, both curative and palliative, depending on whether the drug is used to treat or control advanced cancer. It can be applied for:

• Breast cancer: As a component of anthracycline-based regimens like AC.
• Hodgkin's lymphoma: As a component of the ABVD regimen.
• Aggressive B cell lymphomas: As a component of CHOP-based chemotherapy regimens.
• Acute leukemia: In treatment protocols for certain acute leukemia.
• Soft tissue and bone sarcomas: For certain sarcomas.
• Other cancers: Selected ovarian, bladder, thyroid, and other cancers.

The specifics of using a doxorubicin 200mg injection will depend on the particular type and stage of cancer, the objective of treatment, and the patient’s condition. However, the previous administration of doxorubicin injection, daunorubicin, epirubicin, and other anthracyclines should be taken into account due to the increased risk of cardiotoxicity with total exposure to this drug class.

Doxorubicin 200mg injection functions by interfering with the DNA of cancerous cells, preventing them from reproducing. It works by penetrating the cancer cell and disrupting the structure of its DNA and by inhibiting the activity of topoisomerase II, an enzyme responsible for DNA replication. As a result, the DNA experiences significant damage, which is impossible to repair by the cell. Moreover, doxorubicin injection is capable of generating free radicals and causing further harm to the cell.

Anthracycline breast-cancer evidence: It is clear from large-scale studies and meta-analyses that anthracycline chemotherapy with drugs like doxorubicin 200mg injection can be used effectively in the treatment of breast cancer in appropriate patients.

ABVD/CHOP evidence: Long-term clinical evidence from studies has demonstrated that doxorubicin injection-based chemotherapies like ABVD for Hodgkin's disease and CHOP for aggressive non-Hodgkin lymphomas can play a key role in treatment.

There are many potential side effects associated with Doxorubicin Hydrochloride 200mg Injection, which can be either common or severe side effects that need medical attention.

Common side effects

• Nausea
• Vomiting
• Hair loss
• Mouth sores
• Fatigue
• Neutropenia
• Anemia
• Temporary red/orange urine

Serious side effects requiring prompt medical attention

• Cardiomyopathy/heart failure
• Severe neutropenic infection or sepsis
• Severe tissue injury after extravasation
• Secondary AML/MDS
• Severe liver dysfunction

​Important: The actual dose is decided by the oncologist based on the cancer type, treatment regimen, body surface area, liver function, and previous anthracycline exposure.

If an infusion is missed, contact the oncology department. Do not make up or reschedule the dose yourself. The team will reassess blood counts, infection status, cardiac risk and organ function before setting the next treatment date.

• Blood tests are performed while using Doxorubicin Hydrochloride 200mg Injection to test for red blood cells, white blood cells, and platelets.
• The function of the heart can be tested through LVEF in order to assess the working of the heart.
• Tests for the functioning of the liver are performed along with the tests for bilirubin.
• The injection site for the IV should be tested for any pain, burning sensation, redness, or swelling.
• The overall amount of exposure to anthracycline drugs is calculated since it increases the chance of developing heart problems.
  

• Bartlett, N. L., Niedzwiecki, D., Johnson, J. L., Friedberg, J. W., Johnson, K. B., Van Besien, K., ... & Canellos, G. P. (2007). Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of Oncology, 18(6), 1071-1079.  https://www.sciencedirect.com/science/article/pii/S0923753419379189​
• Dunleavy, K., Fanale, M. A., Abramson, J. S., Noy, A., Caimi, P. F., Pittaluga, S., ... & Wilson, W. H. (2018). Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. The Lancet Haematology, 5(12), e609-e617. ​https://pubmed.ncbi.nlm.nih.gov/30501868/​
• Bisht, A., Avinash, D., Sahu, K. K., Patel, P., Das Gupta, G., & Kurmi, B. D. (2025). A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Delivery and Translational Research, 15(1), 102-133. ​https://europepmc.org/article/MED/38884850​
• Santoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., ... & Rankin, E. (1995). Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology, 13(7), 1537-1545. ​https://pubmed.ncbi.nlm.nih.gov/7602342/​
• Speth, P. A. J., Van Hoesel, Q. G. C. M., & Haanen, C. (1988). Clinical pharmacokinetics of doxorubicin. Clinical pharmacokinetics, 15(1), 15-31. https://pubmed.ncbi.nlm.nih.gov/3042244/​